Why new obicetrapib data matters for NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma (NasdaqGM:NAMS) is back in focus after announcing upcoming presentations of new safety and efficacy data for its oral hypercholesterolemia therapy, obicetrapib, at a major scientific conference.

For investors, these data updates offer another reference point on how the company’s late stage pipeline is progressing within cardiometabolic disease, an area where many patients still face limited or hard to tolerate treatment options.

NewAmsterdam Pharma’s 1 year total shareholder return of 67.45% and 3 year total shareholder return of about 2 times, alongside a 30 day share price return of 9.45% to US$32.67, point to building momentum as investors weigh fresh obicetrapib data against recent governance and audit updates.

If this kind of cardiometabolic story has your attention, it can be useful to see what else is moving in related areas by scanning 40 healthcare AI stocks

With revenue of US$22.57m against a reported loss of US$212.73m and a recent share price of US$32.67, plus valuation tools pointing to a possible discount, is NewAmsterdam still misunderstood, or is the market already pricing in future growth?

Discounted cash flow points to a wide gap versus the current price

NewAmsterdam Pharma is trading at $32.67, while the SWS DCF model estimates the value of its future cash flows at $139.30, which implies a large gap between market price and modelled fair value.

The DCF approach projects the company’s expected future cash flows and then discounts them back to today using a required rate of return, so that long term opportunities and risks are folded into a single present value figure.

For a late stage biotech with US$22.57m in revenue and a reported loss of US$212.73m, this kind of model places most of the weight on how obicetrapib and the wider cardiometabolic pipeline could translate into future cash generation rather than current earnings.

With the stock trading at what is described as a 76.5% discount to this DCF estimate and analysts also indicating a higher price target, the key question for you is whether those future cash flow assumptions feel realistic given the company’s stage and risk profile.

Result: DCF Fair value of $139.30 (UNDERVALUED)

However, the story can change quickly if obicetrapib trial readouts disappoint or if ongoing losses of US$212.73m weigh more heavily on sentiment.

Why a multiple based check sends a different message

While the SWS DCF model points to a large gap between price and estimated fair value, the simpler P/B check is less generous. NewAmsterdam trades at 5.7x book value, which is higher than the US biotechs industry average of 2.4x and cheaper than its peer group average of 6.6x, so the stock looks expensive versus the wider sector but not versus closer peers. The tension between a rich P/B and a discounted DCF leaves you asking which signal should carry more weight at this stage of the company’s lifecycle.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out NewAmsterdam Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on value and risk often create the most interesting set ups. If this story has your attention, review the numbers, recent updates and sentiment indicators for yourself, then weigh the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If NewAmsterdam has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late when the next opportunity emerges.

• Scan for quality at a discount by checking out 47 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect them.
• Lock in potential income streams by reviewing 10 dividend fortresses that offer higher yields with an emphasis on resilience.
• Get ahead of the crowd by exploring the screener containing 22 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.